In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted West Pharmaceutical Services, Inc. (NYSE:WST) as a performance contribtor.
West Pharmaceutical Services, Inc. (NYSE:WST) is a leading manufacturer and distributor of containment and delivery systems for injectable drugs and healthcare products
On August 5, 2026, West Pharmaceutical Services, Inc. (NYSE:WST) closed at $351.02 per share, reflecting a market capitalization of $24.7 billion. West Pharmaceutical Services, Inc. (NYSE:WST) posted a one-month return of -1.86%, while its shares gained 45.93% over the past 52 weeks. Conestoga Capital Advisors stated the following regarding West Pharmaceutical Services, Inc. (NYSE:WST) in its Q2 2026 investor letter: “West Pharmaceutical Services, Inc. (NYSE:WST) develops drug containment and delivery systems for injectable pharmaceuticals and biologic therapies.
The stock moved higher following another quarter of broad based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Organic revenue increased 15%, and management reinstated its favorable long-term growth outlook as strong demand from biologics and GLP-1 therapies continues to support growth across the portfolio. This quarter seemingly signaled a return to normalized growth rates following several years of post-COVID de-stocking.” West Pharmaceutical Services, Inc. (NYSE:WST) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.